Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Merck & Co., Inc.
Type
Public
Traded as NYSE: MRK
Dow Jones Industrial Average Component
S&P 500 Component
Industry Pharmaceuticals
Founded 1891 as a subsidiary of Merck (founded 1668)
1917 as an independent company
Headquarters Kenilworth, New Jersey, United States
Key people
Kenneth Frazier
(Chairman, President and CEO)
Products Gardasil
Singulair
Propecia/Proscar
Zocor Vioxx Fosamax
Revenue Increase US$ 48.047 billion (2011)
Operating income
Decrease US$ 7.334 billion (2011)
Net income
Decrease US$ 6.272 billion (2011)
Total assets Decrease US$ 105.128 billion (2011)
Total equity Decrease US$ 56.943 billion (2011)
Number of employees
76,000 (Dec 2013)
Website Merck.com

Merck & Co., Inc. (NYSE: MRK), d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck headquarters is located in Kenilworth, New Jersey. The company was established in 1891 as the United States subsidiary of the German company Merck (founded 1668). Merck & Co. was confiscated by the US government during World War I and subsequently established as an independent American company. It is the world's seventh largest pharmaceutical company by market capitalization and revenue.

H. K. Mulford Company
(Acq 1929)

Sharp & Dohme, Inc
(Acq 1953)

Medco Containment Services Inc
(Acq 1993, Spun off 2003)

Schering-Plough
(Acq 2009)

Nobilon
Combined into Organon BioSciences

Diosynth
Combined into Organon BioSciences

Intervet
Combined into Organon BioSciences

Organon International
Combined into Organon BioSciences

Plough, Inc
(Merged 1971, Founded 1908)

Schering Corporation
(Merged 1971, Founded 1851)

Idenix Pharmaceuticals
(Acq 2014)

Cubist Pharmaceuticals
(Acq 2014)

Trius Therapeutics
(Acq 2013)

Optimer Pharmaceuticals
(Acq 2013) Adolor

OncoEthix
(Acq 2015)

Investment goal date:
Dividends reinvested
Merck & Co., Inc. MRK report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-02
--
--
Q3 2017
2017-10-27
1.1100
-0.0200
Q2 2017
2017-07-28
1.0100
0.7100
Q1 2017
2017-05-02
0.8800
0.5600
Q4 2016
2017-02-02
0.8900
-0.2200
Q3 2016
2016-10-25
1.0700
0.7800
Q2 2016
2016-07-29
0.9300
0.4300
Q1 2016
2016-05-05
0.8900
0.4000
Q4 2015
2016-02-03
0.9300
0.3500
Q3 2015
2015-10-27
0.9600
0.6400
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF AMERICA CORP /DE/
38465188
Bank of New York Mellon Corp
43102715
BlackRock Fund Advisors
48120535
BlackRock Group LTD
26777686
BlackRock Inc.
183162890
BlackRock Institutional Trust Company, N.A.
75624644
Capital World Investors
106655337
FRANKLIN RESOURCES INC
26218539
GEODE CAPITAL MANAGEMENT, LLC
27574806
JPMORGAN CHASE & CO
35963430
NORTHERN TRUST CORP
35875118
PRICE T ROWE ASSOCIATES INC /MD/
51266378
STATE STREET CORP
123067605
Vanguard Group, Inc
190831858
WELLINGTON MANAGEMENT CO LLP
116161747
Major Shareholders
Name Relationship
Total Shares
Holding stocks
FRAZIER KENNETH C
0.0300% (600304)
MRK / XOM /
KELLOGG PETER N
0.0100% (149553)
CELG / MBLX / MRK /
Deese Willie A
0.0100% (133759)
MRK / PEG / XRAY /
% ()